Sector News

Pfizer whacks 150 jobs at New York site

August 3, 2016
Life sciences

More job cuts are coming to Pfizer’s Pearl River, NY, site as the drug giant closes out vaccine manufacturing there by the end of the year.

The company recently updated the state that it would be eliminating 151 employees between Aug. 20 and Oct. 28. The cuts include 48 union employees and 103, nonunion employees, according to a so-called WARN notice.

Pfizer spokeswoman Susan Rutledge confirmed the cuts today and said that when they are complete about 50 employees will remain to complete the “decommissioning” of the vaccine production operations there.

Home to Wyeth before Pfizer gobbled it up in 2009 in $68 billion deal, the site once had 4,000 employees. But the latest rounds of cuts will leave about 700 employees in oncology drug production and research and development operations, Rutledge said. The company previously eliminated consumer health production at Pearl River.

Rutledge said Pfizer last year sold off the 200-acre developed portion of the site to a real estate investment group and that it retained a 25-acre facility where a small group of oncology production employees remain, along with some R&D operations.

Pearl River was among sites around the world that in 2010 Pfizer identified for elimination or cuts as part of a post-Wyeth buyout manufacturing consolidation. At the time it said it planned to shut down operations at 8 manufacturing sites in Ireland, Puerto Rico, and the U.S. by the end of 2015, and reduce operations at 6 other plants in Germany, Ireland, Puerto Rico, the U.K. and the U.S.

Like its peers, Pfizer is now more focused on biologics manufacturing. The company is seeking approval for a €300 million to €400 million ($440.5 million) biologics plant expansion in Dublin, Ireland that would lead to 350 new jobs and allow Pfizer to expand capacity for Enbrel plus other drugs. It also intends to invest $200 million to build a 175,000-square-foot facility at its campus in Andover, MA, to produce complex biologics and vaccines.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach